Fusion Pharma is also planning to advance its pre-clinical compound FPI-1966 into clinical development next year. HAMILTON, ON and BOSTON, June 25, 2020 – — Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. Per the firm’s most recent regulatory filing, it plans to use the net proceeds ‘to fund the development FPI-1434 as a monotherapy, to advance the development of combination therapies of FPI-1434 with checkpoint inhibitors and DDRIs, including PARP inhibitors, to advance FPI-1966, to further develop and expand our clinical pipeline and for ongoing research and development activities and to fund working capital and other general corporate activities.’. On May 29, 2020, Repare Therapeutics Inc., a St-Laurent, Québe based precision oncology company, officially filed for IPO to list its shares on NASDAQ with the proposed symbol “RPTX”. About FUSN. Major competitive vendors that provide or are developing treatments include: Fusion’s recent financial results are typical of a clinical stage biopharma in that they feature no revenue and significant R&D and G&A expenses associated with advancing its pipeline. Fusion said it has applied to list its shares on the Nasdaq Global Market under the symbol FUSN. Its main drug, FPI-1434, has immense potential if it is successful, but it is the company’s only drug being tested and is in an early stage. The firm is a Phase 1 clinical stage biopharma … Print. This represents a forecast CAGR (Compound Annual Growth Rate) of 15.0% from 2019 to 2027. The Fusion Pharmaceuticals IPO trades Friday. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 22.26%. This site is protected by reCAPTCHA and the Google The evolution of radiopharmaceuticals. IPO stocks can be very volatile in the days immediately after an IPO. Fusion Pharmaceuticals (FUSN) raised $212.5 million with an initial public offering late Thursday that priced high but performed poorly despite heightened interest from investors. Fusion Pharmaceuticals is registered under the ticker NASDAQ:FUSN . To receive automatic notification of new IPO activity, click the "+ Follow" link at the top right of the page. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. Fusion Pharmaceuticals is funded by 16 investors. Quick Take. Information provided is for educational purposes only, may be incomplete or out of date, and does not constitute financial, legal, or investment advice.). Their latest funding was raised on Jan 13, 2020 from a Venture - Series Unknown round. The Fusion Pharmaceuticals IPO began trading Friday afternoon. Lost your password? Their stock opened with $17.00 in its Jun 25, 2020 IPO. Fusion Pharmaceuticals (NASDAQ:FUSN) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.. Privacy Policy and All of the shares are being offered by Fusion. All of the shares are being offered by Fusion. (I have no position in any stocks mentioned as of the article date, no plans to initiate any positions within the next 48 hours, and no business relationship with any company whose stock is mentioned in this article. Morgan Stanley is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 66.8% since their IPO. Fusion Pharmaceuticals. Recently, I’ve seen more life science IPOs seek $125 million in new capital, whereas in previous periods the typical norm was around $75 million. Key elements driving this expected growth are a rising prevalence of breast cancer and lung cancer worldwide as well as increasing reimbursement policies and significant development activities by biopharmaceutical firms. The firm is a … Fusion Pharmaceuticals (FUSN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Write to Colin Kellaher at colin.kellaher@wsj.com. To listen to an audio version of this report, click on the graphic below: Boston, Massachusetts-based Fusion was founded to advance treatment candidates using its 'Targeted Alpha Therapies' platform to 'connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors.'. Dr. ... Dr. Lee has served in positions of increasing responsibility, leading new product strategy, contributing to the IPO, establishing the commercial organization, building infrastructure to enable patient access, and leading multiple new product launches. Remember me. Just like Fusion Pharmaceuticals, the Akouos IPO raised $212.5 million, pricing 12.5 million shares at $17, above its initial price range of $14 to $16. Fusion Pharmaceuticals (FUSN) raised $212.5 million with an initial public offering late Thursday that priced high but performed poorly despite heightened interest from investors. Fusion Pharmaceuticals Inc. on Monday said it expects to sell 8.35 million shares at $14 to $16 apiece in its initial public offering. The lockup period of Fusion Pharmaceuticals Inc. (FUSN) ends on December 23.. Canada-based Fusion Pharmaceuticals is a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines based on its proprietary platform called Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. Fusion Pharmaceuticals has filed for a $100 million IPO, which it intends to use to further developments into its new drug. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO … General Information: Business: ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. Management’s presentation of the company roadshow is available here. The Fusion Pharmaceuticals IPO underwriters included Morgan Stanley, Jefferies and Cowen. Become a Subscriber. Fusion Pharmaceuticals, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals (FUSN) has priced its IPO of 12.5M common shares at $17.00/share, for expected gross proceeds of $212.5M. Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. Jun 22, 2020 The company is advancing drug programs for the treatment of solid tumor cancers. 8 months ago - Investors Business Daily. Terms and Conditions Privacy Center Disclosures Member User Agreement Corrections Cookies Accessibility. Everything you need to know about the Fusion Pharmaceuticals IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. Management is led by founder and Chief Executive Officer John Valliant, Ph.D., who was previously CEO at the Centre for Probe Development and Commercialization, which he also founded. Assuming a successful IPO at the midpoint of the proposed price range, the company’s enterprise value at IPO would approximate $562.7 million. The stock closed right where it started, at 17, on the stock market … Fusion Pharmaceuticals is the second notable Canadian biotech company that has filed for IPO on NASDAQ. Fusion Pharmaceuticals (FUSN) has filed to raise $125 million from … The SCOOP ratings should not be taken as investment advice. - Renaissance Capital Fusion Pharmaceuticals started at overweight with $23 stock price target at Morgan Stanley Jul. On June 25, 2020, Fusion Pharmaceuticals announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. Given the firm’s extremely early stage of development, having just entered Phase 1 safety trials and its single product approach, the IPO may be more suited to institutional investors with a long-term hold time frame. Password. Below is the current status of the company’s drug development pipeline: Investors in the firm have invested at least $103.4 million and include HealthCap, Varian Medical Systems (VAR), Johnson & Johnson, Canada Pension Plan, TPG Biotechnology Partners, OrbiMed, and Seroba Life Sciences Fund. Expected IPO Pricing Date: June 25, 2020. Below are the company’s financial results for the past two and ¼ years (audited PCAOB for full years): As of March 31, 2020, the company had $67.4 million in cash and $16.8 million in total liabilities (unaudited, interim). Fusion Pharmaceuticals Sets IPO at 8.35 Million Shares, Sees Pricing at $14-$16 Each (Jun-2020) Source: www.morningstar.com Tue, Jun 30, 2020 by Spoke Support Intel When did Fusion Pharmaceuticals IPO? 21, 2020 at 10:38 a.m. Filed 2020-06-05 Terms Added 2020-06-22 Terms Changed 2020-06-24: For IPO Boutique's "scale of 1 to 5" BUY rating on Fusion Pharmaceuticals Inc., and … The IPO – which would be the second largest by a Canadian biotech after last week’s debut by Repare Therapeutics Inc. – values Fusion at US$583-million to US$700-million. Hamilton’s Fusion Pharmaceuticals Inc. is set to go public as early as this week after setting an initial price range for its Nasdaq offering on Monday that would see … The gross proceeds, prior to the 30-day greenshoe option, is expected to be US$212.5 million. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Fusion Pharmaceuticals (FUSN) has filed to raise $125 million from the sale of its common stock in a U.S. IPO, according to an amended registration statement. Fusion Pharmaceuticals has raised a total of $170.9M in funding over 4 rounds. FUSN intends to sell 8.35 million shares of common stock at a midpoint price of $15.00 per share for gross proceeds of approximately $125.0 million, not including the sale of customary underwriter options. The company is advancing drug programs for the treatment of solid tumor cancers. Fusion Pharma is using targeted alpha therapeutics to improve the safety of radiopharmaceuticals. Solid tumor biotech Fusion Pharmaceuticals prices upsized IPO at $17, above the range June 26, 2020 Fusion Pharmaceuticals, a Phase 1 biotech developing radiopharmaceuticals for solid tumors, raised $213 million by offering 12.5 million shares at $17, above the range of $14 to $16. According to a 2019 market research report by ResearchAndMarkets, the global market for solid tumor treatments was estimated at $121.3 billion in 2018 and is expected to reach $424.6 billion by 2027. IPO Boutique comments on Fusion Pharmaceuticals Inc. (FUSN) This content is restricted to IPO Boutique Subscribers. X Fusion Pharmaceuticals stock initially climbed 8%, then pulled back. All of the shares are being offered by Fusion. Fusion is seeking a larger than usual IPO amount to fund its program development. The Life Sciences Capital Markets team advised Fusion Pharmaceuticals Inc. on its initial public offering of 12,500,000 common shares at a public offering price of $17.00. This is a top-tier performance for all major underwriters during the period. At the $15 midpoint of that range, the Hamilton, Ontario, clinical-stage oncology company said it expects net proceeds of about $111.9 million, or roughly $129.4 million if the underwriters exercise an option to buy an additional 1.25 million shares. Below is a brief overview video of the firm's TAT approach: The firm's sole drug candidate, FPI-1434, is in Phase 1 monotherapy safety trials and seeks to deliver alpha particle payloads to solid tumors expressing IGF-1R (Insulin-like Growth Factor - 1 Receptor). Username or Email. Akouous is developing therapies for inner ear disorders. * FUSION PHARMACEUTICALS INC NOW SEES IPO OF 12.5 MILLION SHARES PRICED BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING Source text for Eikon: https://bit.ly/2VfCQJm Further company coverage: Disclaimer. Terms of Service apply. As to valuation, management is asking investors to pay an enterprise value of $563 million which is above the typical range for biopharma IPOs. In a filing with the Securities and Exchange Commission, Fusion said it would have about 38.8 million shares outstanding after the IPO, assuming exercise of the overallotment option, for a valuation of about $581.5 million at the $15-a-share midpoint. Fusion said it would use part of the proceeds for the development of FPI-1434, its lead product candidate, as monotherapy and in combination therapies. The market opportunity for treating solid tumors is enormous, possibly the largest single market within the cancer space, on a global basis. Management has disclosed no collaborations, although its in-licensed antibody from Immunogen had been developed in conjunction with Sanofi, although it ‘failed to demonstrate sufficient positive therapeutic efficacy’ in those trials. © Copyright 2021 Morningstar, Inc. All rights reserved. Listed underwriters of the IPO are Morgan Stanley, Jefferies, Cowen and Wedbush PacGrow. Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Fusion's major shareholders include Varian Medical Systems Inc., which owns an 11.3% stake, and Johnson & Johnson, which holds a roughly 10.4% interest. Morgan Stanley, Jefferies, and Cowen acted as lead managers on the deal. No existing shareholders have indicated an interest to purchase shares at the IPO price, a potentially negative signal of the lack of investor support for the IPO. Fusion… Fusion Pharma's lead program advances in early-stage solid tumor study 10.12.20 Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors For its lead program, the firm has recently entered Phase 1 safety trials and expects initial topline data in 3 - 6 months. Fusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share. Biotech Akouos Jumps As Trading Begins. FUSN is still a very early stage company with a single product, so the IPO is high risk and may be more suited to institutional investors with a long-term hold time frame. Fusion Pharmaceuticals Inc. on Monday said it expects to sell 8.35 million shares at $14 to $16 apiece in its initial public offering. Fusion Pharmaceuticals Now Sees IPO Of 12.5 Million Shares Priced Between $14.00 And $16.00 Per Share - SEC Filing.
Wagjag Niagara Falls, New York, War Games General Beringer, Partially In A Sentence, Holy Crepes Clearwater Fl, Hajar Churashir Maa Book Online, 2016 Gmc Sierra 1500,